Transactions

Our broad-based transaction experience extends across a range of situations, industries and enterprise values

Type

Industry

Capital One Financial Corporation

Announced: February 19, 2024
Value: $35.3 billion
Status: Pending

Exclusive financial advisor to Capital One on its acquisition of Discover

Paramount Global

Announced: July 7, 2024
Value: $28 billion
Status: Pending

Exclusive financial advisor to the Special Committee of Paramount in Paramount's merger with Skydance

Endeavor Group Holdings, Inc.

Announced: April 2, 2024
Value: $25 billion
Status: Pending

Exclusive financial advisor to the Special Committee of Endeavor on its sale to Silver Lake

R1 RCM Inc.

Announced: August 1, 2024
Value: $8.9 billion
Status: Pending

Lead financial advisor to TowerBrook and CD&R in their acquisition of R1 RCM

ChampionX Corporation

Announced: April 2, 2024
Value: $8.2 billion
Status: Pending

Exclusive financial advisor to ChampionX on its sale to SLB

Waste Management, Inc.

Announced: June 3, 2024
Value: $7.2 billion
Status: Pending

Exclusive financial advisor to Waste Management on its acquisition of Stericycle

Squarespace, Inc.

Announced: May 13, 2024
Value: $7.2 billion
Status: Pending

Exclusive financial advisor to the Special Committee of Squarespace’s Board of Directors

PowerSchool Holdings, Inc.

Announced: June 7, 2024
Value: $5.6 billion
Status: Pending

Exclusive financial advisor to the Special Committee of the PowerSchool Board of Directors

Alpine Immune Sciences, Inc.

Announced: April 10, 2024
Value: $4.95 billion
Status: Closed

Exclusive financial advisor to Alpine on its sale to Vertex

Telephone and Data Systems, Inc.

Announced: May 28, 2024
Value: $4.4 billion
Status: Pending

Financial advisor to TDS (controlling shareholder of UScellular) on the sale of UScellular's wireless operations and select spectrum assets to T-Mobile

CymaBay Therapeutics, Inc.

Announced: February 12, 2024
Value: $4.3 billion
Status: Closed

Lead financial advisor to CymaBay on its sale to Gilead

The Cigna Group

Announced: January 31, 2024
Value: $3.7 billion
Status: Pending

Lead financial advisor to Cigna on the sale of its Medicare Businesses and CareAllies to HCSC

MorphoSys AG

Announced: February 5, 2024
Value: €2.7 billion
Status: Closed

Exclusive financial advisor to MorphoSys on its sale to Novartis

Morphic

Announced: July 8, 2024
Value: $3.2 billion
Status: Closed

Exclusive financial advisor to Morphic in its sale to Eli Lilly

Eyebiotech Limited

Announced: May 29, 2024
Value: Up to $3 billion
Status: Closed

Exclusive financial advisor to Eyebio on its sale to Merck

C&S

Announced: April 22, 2024
Value: $2.9 billion
Status: Pending

Exclusive financial advisor to C&S on its acquisition of 579 stores and various facilities that have become available from the Kroger and Albertsons merger

Agiliti Inc.

Announced: February 26, 2024
Value: $2.5 billion
Status: Closed

Exclusive financial advisor to the Special Committee of Agiliti on its sale to THL Partners

Fusion Pharmaceuticals Inc.

Announced: March 19, 2024
Value: Up to $2.4 billion
Status: Closed

Exclusive financial advisor to Fusion on its sale to AstraZeneca

Infinera Corporation

Announced: June 27, 2024
Value: $2.3 billion
Status: Pending

Exclusive financial advisor to Infinera in its sale to Nokia

Inhibrx

Announced: January 22, 2024
Value: Up to $2.2 billion
Status: Closed

Exclusive financial advisor to Inhibrx on its sale to Sanofi and pro rata distribution of shares in a new publicly traded biopharma company

Ambrx, Inc.

Announced: January 8, 2024
Value: $2 billion
Status: Closed

Lead financial advisor to Ambrx on its sale to Johnson & Johnson

Mariana Oncology, Inc.

Announced: May 2, 2024
Value: $1.75 billion
Status: Closed

Financial advisor to Mariana on its sale to Novartis

HireRight Holdings Corporation

Announced: February 16, 2024
Value: $1.65 billion
Status: Closed

Exclusive financial advisor to the Special Committee of HireRight on its sale to General Atlantic and Stone Point

Keysight Technologies, Inc.

Announced: March 28, 2024
Value: $1.5 billion
Status: Pending

Joint-lead financial adviser to Keysight on its acquisition of Spirent Communications

Numab Therapeutics AG

Announced: May 28, 2024
Value: $1.25 billion
Status: Closed

Lead financial advisor to Numab Therapeutics on its sale of NM-26, a bi-specific antibody, to Johnson & Johnson

Jnana Therapeutics Inc.

Announced: August 1, 2024
Value: Up to $1.125 billion
Status: Closed

Exclusive financial advisor to Jnana on its sale to Otsuka

Cardior Pharmaceuticals GmbH

Announced: March 25, 2024
Value: Up to $1.1 billion
Status: Closed

Exclusive financial advisor to Cardior on its sale to Novo Nordisk

Amolyt Pharma SAS

Announced: March 14, 2024
Value: Up to $1.05 billion
Status: Closed

Lead financial advisor to Amolyt Pharma on its sale to AstraZeneca

Escient Pharmaceuticals, Inc.

Announced: April 23, 2024
Value: $750 million
Status: Closed

Financial advisor to Escient Pharmaceuticals on its sale to Incyte Corporation

Harpoon Therapeutics, Inc.

Announced: January 8, 2024
Value: $680 million
Status: Closed

Exclusive financial advisor to Harpoon on its sale to Merck

Kimberly-Clark Corporation

Announced: April 7, 2024
Value: $640 million
Status: Closed

Financial advisor to Kimberly-Clark on the sale of its Personal Protective Equipment business to Ansell

Alimera Sciences, Inc.

Announced: June 24, 2024
Value: Up to $435 million
Status: Closed

Lead financial advisor to Alimera in its sale to ANI Pharmaceuticals

Accor SA

Announced: March 12, 2024
Value: €275 million
Status: Closed

Exclusive financial advisor to Accor on its share repurchase from Jinjiang International

The Simply Good Foods Company

Announced: April 29, 2024
Value: $280 million
Status: Closed

Exclusive financial advisor to Simply Good Foods on its acquisition of Only What You Need (OWYN)

Celsius Therapeutics, Inc.

Announced: June 27, 2024
Value: $250 million
Status: Closed

Exclusive financial advisor to Celsius in its sale to AbbVie

Fleet Complete

Announced: September 18, 2024
Value: $200 million
Status: Closed

Financial advisor to Fleet Complete in its sale to Powerfleet

Vertex, Inc.

Announced: August 7, 2024
Value: $180 million
Status: Closed

Exclusive financial advisor to Vertex in its acquisition of Ecosio GmbH

The Children's Place, Inc

Announced: February 29, 2024
Value: $78.6 million
Status: Closed

Exclusive financing advisor to The Children's Place on its financing agreement with Mithaq Capital

Trimble Inc.

Announced: September 15, 2024
Status: Pending

Financial advisor to Trimble in the sale of its global transportation telematics business to Platform Science

Hobbs & Associates

Announced: July 15, 2024
Status: Closed

Financial advisor to Air Control Concepts (formerly known as Hobbs & Associates) on its investment from Blackstone

PharmaCord LLC

Announced: June 6, 2024
Status: Pending

Exclusive financial advisor to PharmaCord on its sale to Permira

Advent International Corporation

Announced: June 5, 2024
Status: Closed

Exclusive financial advisor to Advent International on its strategic investment in Prometheus Group

CapVest Partners LLP

Announced: June 4, 2024
Status: Closed

Financial advisor to CapVest on its partial equity recapitalization of Datasite LLC

Illumina

Announced: June 3, 2024
Status: Closed

Financial advisor to Illumina on its spin-off of GRAIL

Dupont (E. I. du Pont de Nemours and Company)

Announced: May 22, 2024
Status: Pending

Financial advisor to DuPont on its separation into three independent, publicly-traded companies

Proteologix US Inc.

Announced: May 16, 2024
Status: Closed

Exclusive financial advisor to Proteologix on its sale to Johnson & Johnson

Uniti Group Inc.

Announced: May 3, 2024
Status: Pending

Financial advisor to Uniti on its merger with Windstream

IANS

Announced: April 23, 2024
Status: Closed

Exclusive financial advisor to IANS on its strategic investment from Apax Digital

Nexus Pharmaceuticals, Inc.

Announced: April 22, 2024
Status: Closed

Exclusive financial advisor to Nexus on the sale of an injectable medicine manufacturing facility to Eli Lilly

EyeCare Partners, LLC

Announced: April 19, 2024
Status: Closed

Exclusive financial advisor to EyeCare Partners on its private debt exchange and new money investment

eBay Inc.

Announced: April 10, 2024
Status: Closed

Exclusive financial advisor to eBay in its acquisition of Goldin from Collectors, sale of eBay Vault to PSA and commercial agreement with Collectors

Disney

Announced: April 3, 2024
Status: Closed

Advisor to Disney in connection with its proxy contest with Trian Partners and Blackwells, as well as its settlement with ValueAct

Advance Auto Parts Inc.

Announced: March 11, 2024

Exclusive financial advisor to Advance Auto Parts on the announcement of a cooperation agreement with Third Point and Saddle Point

Ventas Inc.

Announced: March 4, 2024
Status: Closed

Financial advisor to Ventas on the announcement of a cooperation agreement with Land & Buildings

Avison Young (Canada) Inc.

Announced: February 26, 2024
Status: Closed

Financial advisor to Avison Young on its recapitalization transaction and new capital investment

Delphix

Announced: February 14, 2024
Status: Closed

Exclusive financial advisor to Delphix on its sale to Perforce

REV Group, Inc.

Announced: February 13, 2024
Status: Pending

Exclusive financial advisor to the Special Committee of REV Group regarding its secondary offering and share repurchase of American Industrial Partners' ownership stake

Dave.com

Announced: January 30, 2024
Status: Closed

Exclusive financial advisor to Dave on its repurchase of a convertible note from FTX

Radiology Partners, Inc.

Announced: January 19, 2024
Status: Closed

Exclusive financial advisor to an ad-hoc group of crossover creditors on Radiology Partners' set of refinancing transactions

Diamond Sports Group, LLC

Announced: January 17, 2024
Status: Pending

Exclusive financial advisor to the ad-hoc group of first lien creditors on Diamond Sports Group's Restructuring Support Agreement and investment from Amazon

Wolverine World Wide, Inc.

Announced: January 11, 2024
Status: Closed

Exclusive financial advisor to Wolverine on the sale of Sperry to Authentic Brands and ALDO

Informa plc

Announced: January 10, 2024
Status: Pending

Financial advisor to Informa on the combination of Informa Tech's digital businesses with TechTarget

Danone S.A.

Announced: January 2, 2024
Status: Closed

Exclusive financial advisor to Danone on the sale of a majority stake in its U.S. premium organic dairy business to Platinum Equity

Showing 1 to 63 of 63
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

At Centerview Partners, our success depends on our people, and we are always looking for talented individuals. Please let us know if you would like to learn more about a career at Centerview.
Our Partners have worked on many of the largest and most complex transactions and corporate situations around the globe over the course of their careers. Learn more about who we are.
New York

Centerview Partners LLC


31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax
London

Centerview Partners UK LLP


1 Sherwood Street

6th Floor

London W1F 7BL

02074099700 | Tel
02074099704 | Fax
Paris

Centerview Partners France SCS


51 Avenue Hoche


Paris 75008

0180200620 | Tel
0180200621 | Fax
Menlo Park

Centerview Partners LLC


1302 El Camino Real

Suite 350

Menlo Park, California 94025

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC


555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax





Copyright © 2008 - 2024 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC